News
OPK
1.195
+1.27%
0.015
Weekly Report: what happened at OPK last week (0406-0410)?
Weekly Report · 3d ago
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks · 04/09 10:40
BUZZ-U.S. STOCKS ON THE MOVE-Hims & Hers, Chewy, Longeveron
Reuters · 04/08 15:51
BUZZ-U.S. STOCKS ON THE MOVE-Delta, Levi's, banks
Reuters · 04/08 13:15
BUZZ-OPKO Health rises as ModeX starts early trial of COVID-19 prevention antibody
Reuters · 04/08 12:50
OPKO Health's ModeX Therapeutics Says First Participants Dosed In Phase 1 Clinical Trial Evaluating MDX2301 For Prevention Of COVID-19
Benzinga · 04/08 12:05
Opko’s ModeX doses first patients in Phase 1 MDX2301 COVID-19 prevention trial
Reuters · 04/08 12:04
Opko unit ModeX doses first patients in Phase 1 COVID-19 prevention trial MDX2301
Reuters · 04/08 12:03
OPKO HEALTH’S MODEX THERAPEUTICS INITIATES CLINICAL TRIAL OF MDX2301 FOR THE PREVENTION OF COVID-19
Reuters · 04/08 12:00
Weekly Report: what happened at OPK last week (0330-0403)?
Weekly Report · 04/06 10:33
Weekly Report: what happened at OPK last week (0323-0327)?
Weekly Report · 03/30 10:33
OPKO Health: The Waiting Game Continues
Seeking Alpha · 03/26 12:50
Weekly Report: what happened at OPK last week (0316-0320)?
Weekly Report · 03/23 10:29
Opko, Prologis, Williams, APA, Paysafe: Insider Moves Exposed
TipRanks · 03/21 13:01
Opko Health Adds Independent Director to Strengthen Governance
TipRanks · 03/19 21:19
Opko Health appoints Subbarao V. Uppaluri as director
Reuters · 03/19 20:50
Vesicor Therapeutics names Michael Tolentino CEO as Luo Feng becomes CSO
Reuters · 03/19 02:43
Weekly Report: what happened at OPK last week (0309-0313)?
Weekly Report · 03/16 10:28
Weekly Report: what happened at OPK last week (0302-0306)?
Weekly Report · 03/09 10:29
OPKO Health Price Target Cut to $1.50/Share From $2.25 by Barrington Research
Dow Jones · 03/02 15:54
More
Webull provides a variety of real-time OPK stock news. You can receive the latest news about Opko Health through multiple platforms. This information may help you make smarter investment decisions.
About OPK
OPKO Health, Inc. is a multinational biopharmaceutical and diagnostics company. The Company’s segments include pharmaceutical and diagnostics. The pharmaceutical segment consists of the pharmaceutical operations it operates in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its global pharmaceutical research and development operations. The diagnostics segment primarily consists of clinical laboratory operations through BioReference and its point-of-care operations. Its pharmaceutical business features Somatrogon (hGH-CTP), a once-weekly human growth hormone injection, and it is marketed under the brand name NGENLA. The Company, through its pharmaceutical division, manufactures and sells Rayaldee, a United States Food and Drug Administration (FDA) approved treatment for secondary hyperparathyroidism (SHPT) in adults with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency.